KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.

Christos C Zouboulis, Athanassios Kyrgidis, Afsaneh Alavi, Gregor B E Jemec, Antonio Martorell, Angelo V Marzano, Hessel H van der Zee, Magdalena B Wozniak, Angela Llobet Martinez, Torben Kasparek, Teresa Bachhuber, Christine-Elke Ortmann, Iryna Lobach, Nicolas Thomas, Shoba Ravichandran, Thrasyvoulos Tzellos

J Eur Acad Dermatol Venereol 39(8) 1421-1430

PMID39425517
PMCIDPMC12291009
DOI10.1111/jdv.20369
发表日期2024-10-19
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

INTRODUCTION: The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS). OBJECTIVE: To evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS. METHODS: Data from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed. Assessments included changes from baseline in IHS4 and severity classification up to Week 52; IHS4-55, IHS4-75, IHS4-90 responses (55%, 75% and 90% reduction in IHS4) and concordance between IHS4-55 and HS clinical response (HiSCR), at Weeks 16 and 52. RESULTS: In total, 1084 patients (SECQ2W = 361; SECQ4W = 360; placebo = 363) were analyzed. At Week 16, SECQ2W and SECQ4W demonstrated a numerically higher reduction in IHS4 from baseline versus placebo (adjusted mean [95% CI]: -10.80 [-12.30 to -9.30] and -9.46 [-10.96 to -7.96] vs. -4.92 [-6.43 to -3.41]); the reduction was maintained until Week 52 in both dose regimens. A greater proportion of patients achieved IHS4-55 with SECQ2W (43.4%) and SECQ4W (39.5%) versus placebo (31.5%) at Week 16, with further improvement at Week 52. Similar trends were observed for IHS4-75 and IHS4-90 responses. While no patients had mild disease based on IHS4 (80.7% had severe and 19.3% had moderate HS) at baseline, a greater proportion of patients were categorized as having mild disease at Week 16 in the SECQ2W (25.9%) and SECQ4W (24.0%) groups versus placebo (16.4%); this trend continued up to Week 52 in both dose regimens. Strong concordance (>85%) was observed between IHS4-55 and HiSCR. CONCLUSIONS: Both SECQ2W and SECQ4W demonstrated efficacy in improving treatment response as measured by IHS4 and reducing disease severity versus placebo at Week 16 and these improvements were sustained through Week 52. These findings support that the dynamic and dichotomous IHS4 can efficiently detect treatment response changes in clinical trial settings. CLINICAL TRIALS REGISTRATION: SUNSHINE (NCT03713619); SUNRISE (NCT03713632).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Comparison of HiSCR versus IHS4 outcome measures., , HiSCR, hidradenitis suppurativa clinical response; HS, hidradenitis suppurativa; IHS4, International Hidradenitis Suppurativa Severity Score System.
非 KM Figure
FIGURE 2FIGURE 2 Change from baseline in IHS4 up to Week 52: (a) SUNSHINE trial; (b) SUNRISE trial; and (c) pooled data. CI, confidence interval; IHS4, International Hidradenitis Suppurativa Severity Score System; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg. The error bars represent standard error. All data are reported as observed. Data from baseline to week 16 are based on mixed effects repeated measures models, with treatment, baseline IHS4, visit, treatment‐by‐visit interaction, and trial were used to estimate the adjusted means and to infer 95% CIs. Data from week 18 to 52 (in grey box) are reported as mean change.
非 KM Figure
FIGURE 3FIGURE 3 Proportion of patients achieving IHS4‐55, IHS4‐75 and IHS4‐90 at Weeks 16 and 52: (a) SUNSHINE trial (b) SUNRISE trial; and (c) pooled data. IHS4, International Hidradenitis Suppurativa Severity Score System; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg. The IHS4‐55, IHS4‐75, and IHS4‐90 indicate 55%, 75%, and 90% reduction in the IHS4 from the baseline, respectively. All data are reported as observed.
非 KM Figure
FIGURE 4FIGURE 4 Shift in the IHS4 severity classification grade from baseline to Week 16 and Week 52: (a) SUNSHINE trial; (b) SUNRISE trial; and (c) pooled data. IHS4, International Hidradenitis Suppurativa Severity Score System; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg. IHS4 disease severity: mild: ≤3, moderate: 4–10, severe: ≥11. All data are reported as observed.
非 KM Figure